GLP-1 receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-21. Numbers and descriptions here follow the published literature rather than marketing material.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Includes the 39-residue backbone and the attached fatty diacid |
| Molecular weight | Approximately 4813 Da | Average mass; the monoisotopic value is slightly lower |
| Receptor targets | GIP receptor and GLP-1 receptor | Dual engagement defines the pharmacological class |
| Backbone length | 39 amino acids | Sequence modified from native glucose-dependent insulinotropic polypeptide |
| Albumin interaction | Reversible, mediated by the fatty diacid | Slows renal clearance and lengthens circulation time |
纯度评估通常综合反相色谱、体积排阻色谱与质谱三方面信息：前者反映疏水性杂质，后者反映聚集体，质谱则确认分子量与主要降解产物。有关降解途径的完整图谱——例如脱酰胺、氧化与水解各占多大比例——在不同储存条件下仍有差异，属于需要逐案验证的问题。
质量控制环节关注外观、含量、纯度、有关物质、水分与微生物限度等项目。检测结果需要有对照品和系统适用性数据支持，单次测定不足以判定批次的稳定性。实验室之间方法转移时，色谱柱品牌与梯度差异常导致保留时间漂移，因此方法验证十分必要。
固体状态的 tirzepatide 通常以冻干粉形式保存，推荐在低温、避光、干燥条件下存放，常见区间为 2 至 8 摄氏度，长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出，从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
== History == The earliest human activity in Ningxia can be traced back to 30,000 years ago, with remains of the Shuidonggou culture found in Lingwu. As a frontier zone between nomadic pastoralists and sedentary farmers, Ningxia was a frequent seat of war and incursions by non-Chinese tribes. Ningxia and its surrounding areas were incorporated into the Qin as the Beidi Commandery as early as the 3rd century BC. To pacify the region, the imperial government established military colonies to reclaim land. In addition, horse pasturages were founded under the Imperial Stud to safeguard the supply of army horses, as early as the Western Han dynasty (206 BC – AD 9). Throughout the Han dynasty and the Tang dynasty there were several large cities established in the region. The Liang Province rebellion at the end of the Han dynasty affected Ningxia. By the 11th century the Tangut people had established the Western Xia dynasty on the outskirts of the then-Song dynasty. Jews also lived in Ningxia, as evidenced by the fact that in 1489, after a major flood destroyed Torah scrolls in Kaifeng, a replacement set was sent to the Kaifeng Jews by the Ningbo and Ningxia Jewish communities. It then came under Mongol domination after Genghis Khan conquered Yinchuan in the early 13th century. Muslims from Central Asia also began moving into Ningxia from the west. By the late 17th century, Ningxia had become a weaving centre, producing many early Chinese carpets. The Muslim Dungan Revolt of the 19th century affected Ningxia. In 1914, Ningxia was merged with the province of Gansu.
Vector-based methods have resulted in aggregation and endosomal sequestration of quantum dots while electroporation can damage the semi-conducting particles and aggregate delivered dots in the cytosol. Via cell squeezing, quantum dots can be efficiently delivered without inducing aggregation, trapping material in endosomes, or significant loss of cell viability. Moreover, it has shown that individual quantum dots delivered by this approach are detectable in the cell cytosol, thus illustrating the potential of this technique for single-molecule tracking studies.
== External links == Glucagon-Like Peptide-2 Receptor at the U.S. National Library of Medicine Medical Subject Headings (MeSH) This article incorporates text from the United States National Library of Medicine, which is in the public domain.
Sources: en.wikipedia.org
== History == In the 1960s, Werner Bollag of Roche Laboratories began studying 13-cis retinoic acid as a treatment for skin cancer. By 1971, Roche showed that the compound was likely ineffective against cancer but useful for treating acne. However, Roche abandoned the product after finding a likelihood that the compound could cause birth defects, as the thalidomide scandal had raised the public's fear of such side effects. In 1975, Gary Peck, a dermatologist at the National Cancer Institute, initiated a collaboration with Hoffmann-La Roche to evaluate the efficacy of isotretinoin for a number dermatological conditions previously managed with retinoic acids, including acne, psoriasis, genetic skin disorders, and skin cancer prevention. After Peck authored an article in 1979 reporting the drug's effectiveness against cystic and conglobate acne, Roche submitted a New Drug Application to the Food and Drug Administration (FDA). While admitting that isotretinoin caused birth defects in rabbits, Roche avoided regulatory scrutiny by excluding pregnant women from its clinical trials and secured FDA approval in 1982. Despite prior correlation of isotretinoin with birth defects, Accutane quickly became the dominant acne treatment prescribed by dermatologists and general practitioners alike. In 1983, the FDA made the unprecedented decision to warn blood banks against accepting the blood of donors taking isotretinoin and instruct women to begin taking contraceptives one month before use.
== Malignant neoplasm of digestive organs and peritoneum (150–159) == 150 Malignant neoplasm of esophagus 151 Malignant neoplasm of stomach 152 Malignant neoplasm of small intestine, including duodenum 153 Malignant neoplasm colon 154 Malignant neoplasm of rectum, rectosigmoid junction, and anus 155 Malignant neoplasm of liver and intrahepatic bile ducts 156 Malignant neoplasm of gallbladder and extrahepatic bile ducts 157 Malignant neoplasm of pancreas 158 Malignant neoplasm of retroperitoneum and peritoneum 159 Malignant neoplasm of other and ill-defined sites within the
{\displaystyle \Delta _{\mathrm {r} }G_{T,p}=\sum _{i=1}^{k}\mu _{i}^{\ominus }\nu _{i}+RT\ln {\frac {\{\mathrm {S} \}^{\sigma }\{\mathrm {T} \}^{\tau }}{\{\mathrm {A} \}^{\alpha }\{\mathrm {B} \}^{\beta }}}}
Sources: en.wikipedia.org
City Manager's office Finance Department Human Resources Department Information Technology Department Municipal Court Parks and Recreation administrative staff Public Works Engineering, Building and Planning divisions. The city provides its own fire department, police department, library system, and also provides both their own water supply and wastewater treatment through the Public Works Operations division. The current wastewater treatment plant was completed in 2009. In total the local government employs around 450 full- and part-time employees with the majority in Police, Fire, and Public Works Operations. The Albany city government was nationally recognized in 2009 and 2010 with the Certificate of Distinction and in 2011 and 2012 with the Certificate of Excellence from the International City/County Management Association (ICMA) for its dedication to improving governmental performance. In 2010, 2011 and 2012, the Sunshine Review awarded Albany an A+ perfect score for government transparency and online accessibility with its website along with other government agencies from around the country. Also in September 2010, the League of Oregon Cities awarded Albany the Good Governance Award for the "Where Does My Money Go? and Albany Dashboard" web applications and featured Albany for governmental transparency. In January 2011, Government Computer News cited Albany as one of ten "Top Public Sector Websites" in the nation for government transparency.
=== Complications === The back legs may become weak and the gait may become stilted or wobbly owing to diabetic neuropathy, which is caused by damage to the myelin sheath of the peripheral nerves due to glucose toxicity and cell starvation, which are in turn caused by chronic hyperglycemia. Most common in cats, the back legs become weaker until the cat displays a plantigrade stance, standing on its hocks instead of on its toes as normal. The cat may also have trouble walking and jumping and may need to sit down after a few steps. Neuropathy sometimes heals on its own within 6–10 weeks once blood sugar is regulated.
Ben Howlett (born 21 October 1988) is a former professional Australian rules footballer who played for the Essendon Football Club in the Australian Football League (AFL). Howlett was selected by Essendon with pick 30 in the 2010 rookie draft, as a 21-year-old from Peel Thunder in the West Australian Football League. His final season with Peel Thunder saw him claim the club's best and fairest award. He was promoted to Essendon's senior list in the 2010 season. Howlett, along with 33 other Essendon players, was found guilty of using a banned performance-enhancing substance, thymosin beta-4, as part of Essendon's sports supplements program during the 2012 season. He and his teammates were initially found not guilty in March 2015 by the AFL Anti-Doping Tribunal, but a guilty verdict was returned in January 2016 after an appeal by the World Anti-Doping Agency. He was suspended for one season which, with backdating, ended in November 2016; as a result, he served approximately fourteen months of his suspension and missed the entire 2016 AFL season. Howlett was delisted at the conclusion of the 2017 AFL season. He returned home to WA and signed with the club he was originally drafted from, Peel Thunder in the WAFL, for the 2018 season. In 2019, Howlett was named captain of the club, taking over from dual premiership captain Gerald Ugle. In Round 9 of the 2021 WAFL season Howlett played his 100th game for Peel Thunder against Swan Districts before announcing his retirement from WAFL footy at the end of that season.
Seborrhoeic dermatitis typically appears as oily, yellowish, flaky skin. Although commonly associated with oily skin, it can also appear on dry scalps or skin, where the flaking may look similar to dandruff. Flakes can be fine, loose, and diffuse; or they can be thick and adherent. In addition to flaky skin, seborrhoeic dermatitis can have areas of red, rashy, inflamed, and itchy skin that coincide with the area of skin flaking, but not all individuals have this symptom. Seborrhoeic dermatitis of the scalp can appear similarly to dandruff. When the scalp is affected, there can be associated temporary hair loss. Such hair loss varies in appearance from diffuse thinning to patchy areas of hair loss. On close inspection, the locations where hair has thinned may have broken stubs of hair and pustules around the hair follicles. Individuals with more pigmented skin tones may experience increased or decreased skin pigmentation in affected areas. Various locations can be affected by seborrhoeic dermatitis. Commonly affected areas include the face, ears, scalp, and across the body. It is less common in intertriginous areas, which are areas where the skin folds and comes into contact with itself, such as the groin or the underarms. Seborrhoeic dermatitis' symptoms are typically mild and appear gradually but are often persistent, lasting weeks to years. Individuals with seborrhoeic dermatitis are subject to recurrent bouts and it may be a lifelong condition. Seborrhoeic dermatitis can also occur quickly and severely in patients with Human Immunodeficiency Virus (HIV).
Sources: en.wikipedia.org
It is a synthetic peptide that activates both the GIP and GLP-1 receptors, making it a dual agonist. Approved products are given by injection rather than by mouth. It is not a small molecule and does not belong to the older sulfonylurea or thiazolidinedione families.
Engaging two receptors recruits signaling pathways that only partly coincide. This can shift the magnitude of effects on insulin release, glucagon levels and appetite relative to selective agents. Whether the pairing delivers benefits beyond a simple sum of the two is still debated in the literature.
The proportional contribution of each receptor to observed clinical effects has not been fully separated. Long-term consequences of continuous dual stimulation are likewise unclear. Investigators continue to probe these points through laboratory and clinical work.
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.